MicroRNA‐135a‐3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer

• DOI: 10.1111/cas.13210
• Publication Date: 2017-02-23T18:40:32Z
• Authors: Satoshi Fukagawa; Kohei Miyata; Fusanori Yotsumoto; Chihiro Kiyoshima; Sung Ouk Nam; Haruchika Anan; Takahiro Katsuda; Daisuke Miyahara; Masaharu Murata; Hiroshi Yagi; Kyoko Shirota; Shin'ichiro Yasunaga; Kiyoko Kato; Shingo Miyamoto
• Keywords: Ovarian Neoplasms; Paclitaxel; Gene Expression Profiling; Antineoplastic Agents; Original Articles; Middle Aged; Prognosis; 3. Good health; Gene Expression Regulation, Neoplastic; Mice; MicroRNAs; 03 medical and health sciences; 0302 clinical medicine; Cell Line, Tumor; Biomarkers, Tumor; Animals; Humans; Female; Cisplatin; Cell Proliferation

Ovarian cancer is the most lethal gynecologic malignancy. Recently, several molecularly targeted anticancer agents have been developed for ovarian cancer; however, its prognosis remains extremely poor. The development of therapy, as well companion diagnostics, required to improve outcomes patients with cancer. In this study, identify micro RNA s (mi s) involved in progression we analyzed serum mi using array and quantitative RT ‐ PCR examined properties expression cells. cancer, high amount miR‐135a‐3p samples was significantly associated favorable clinical prognosis. decreased compared cysts or normal ovaries. SKOV ‐3 ES ‐2 human cells, enhanced induced drug sensitivity cisplatin paclitaxel suppressed cell proliferation xenograft tumor growth. These findings suggest that may be considered a biomarker therapeutic agent